Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With ModernaGlobeNewsWire • 03/03/26
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo ShotZacks Investment Research • 03/02/26
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19Accesswire • 02/27/26
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the costReuters • 02/23/26
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is ClearThe Motley Fool • 02/23/26
Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January.The Motley Fool • 02/21/26
Moderna got the FDA to change its mind and review its flu vaccine after some concessionsMarket Watch • 02/18/26